Sodium thiosulfate-containing pharmaceutical compositions
Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
1. A method for treating platinum-induced ototoxicity, comprising administering to a subject having platinum-induced ototoxicity, a platinum coordination complex in combination with pharmaceutical grade sodium thiosulfate pentahydrate, wherein the pharmaceutical grade sodium thiosulfate pentahydrate contains no greater than about 8 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% of sulfite, contains no greater than about 0.5% of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities.
2. The method of claim 1 , wherein the platinum coordination complex is cisplatin, satraplatin, or carboplatin.
3. The method of claim 2 , wherein the platinum coordination complex is cisplatin.
4. The method of claim 2 , wherein the platinum coordination complex is satraplatin.
5. The method of claim 2 , wherein the platinum coordination complex is carboplatin.
6. The method of claim 1 , wherein the administration is oral.
7. The method of claim 1 , wherein the administration is topical.
8. The method of claim 1 , wherein the administration is intradermal, dermal or transdermal.
9. The method of claim 1 , wherein the administration is intravenous or subcutaneous.
10. The method of claim 1 , wherein the administration is rectal.
11. A method for treating platinum-induced nephrotoxicity, comprising administering to a subject having platinum-induced nephrotoxicity, a platinum coordination complex in combination with pharmaceutical grade sodium thiosulfate pentahydrate, wherein the pharmaceutical grade sodium thiosulfate pentahydrate contains no greater than about 8 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% of sulfite, contains no greater than about 0.5% of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities.
12. The method of claim 11 , wherein the platinum coordination complex is cisplatin, satraplatin, or carboplatin.
13. The method of claim 12 , wherein the platinum coordination complex is cisplatin.
14. The method of claim 12 , wherein the platinum coordination complex is satraplatin.
15. The method of claim 12 , wherein the platinum coordination complex is carboplatin.
16. The method of claim 11 , wherein the administration is oral.
17. The method of claim 11 , wherein the administration is topical.
18. The method of claim 11 , wherein the administration is intradermal, dermal or transdermal.
19. The method of claim 11 , wherein the administration is intravenous or subcutaneous.
20. The method of claim 11 , wherein the administration is rectal.